Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $11.0300 (0.41%) ($11.0300 - $11.0300) on Fri. Mar. 31, 2023. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.37% (three month average) | RSI | 43 | Latest Price | $11.0300(0.41%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | FOLD declines -1.5% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) XBI(60%) IBB(57%) IWO(44%) IWM(43%) IWC(41%) | Factors Impacting FOLD price | FOLD will decline at least -1.185% in a week (0% probabilities). TBT(-21%) VXX(-15%) UUP(-11%) VIXM(-7%) BNDX(-5%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.185% (StdDev 2.37%) | Hourly BBV | -0.2 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $3.78(-65.73%) | Resistance Level | $11.38 | 5 Day Moving Average | $11.09(-0.54%) | 10 Day Moving Average | $11.15(-1.08%) | 20 Day Moving Average | $11.38(-3.08%) | To recent high | -19.2% | To recent low | 0.4% | Market Cap | $2.848b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |